Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa568
Abstract: OBJECTIVES Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the 'Th2' cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We… read more here.
Keywords: explanation; enthesis; entheseal; expression ... See more keywords
Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031031
Abstract: Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased… read more here.
Keywords: efficacy; dupilumab therapy; treatment; dupilumab ... See more keywords
Development of Nodular Lesions after Dupilumab Therapy in Erythrodermic Mycosis Fungoides with Interleukin-13 Receptor alpha2 Expression
Sign Up to like & getrecommendations! Published in 2022 at "Acta Dermato-Venereologica"
DOI: 10.2340/actadv.v102.2234
Abstract: Abstract is missing (Short communication) read more here.
Keywords: nodular lesions; erythrodermic mycosis; lesions dupilumab; development nodular ... See more keywords